Clinical Trials Logo

Filter by:
NCT ID: NCT05728398 Not yet recruiting - Clinical trials for Patient Satisfaction

Music in Interventional Radiology Procedures

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The use of music as medical therapy for the treatment of mental health conditions like depression and anxiety is well established. Furthermore, music is sometimes played in operating rooms and several small single center studies done during cardiology and interventional radiology procedures have demonstrated that the use of music can decrease in the use of sedation medications, pain, and anxiety during the procedures. These past studies have only looked at the impact on the participants, as the music was delivered to the participants only through headphones. This means that the impact of music on the healthcare team was not studied. However, separate systematic literature reviews on the impact of playing music in operating rooms during surgical procedures have highlighted some positive effects music has on the surgeon and the surgical team. The purpose of this study is to evaluate the effects of playing music during interventional radiology procedures on the participants and the healthcare team. One way of studying this is to compare the responses and experience of participants and healthcare team that hear ambient music during the procedure with those who did not.

NCT ID: NCT05733481 Not yet recruiting - Clinical trials for Chronic Total Occlusion of Coronary Artery

Evaluating the Use of the CapBuster System for the Crossing of CTO's in Coronary Arteries

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Evaluate the safety and effectiveness of the CapBuster System medical device in crossing de novo or restenotic chronic total occlusions in coronary arteries

NCT ID: NCT05734079 Not yet recruiting - Colonoscopy Clinical Trials

Impact of Digital Tools on the Quality of Bowel Preparation for Colonoscopy

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

This is a single blinded randomized controlled study. The main question of this study is whether better preparation by making full use of digital tools can increase patient compliance with the preparation methods for colonoscopy, and as a result improve bowel preparation quality and colonoscopy outcomes in a cost-effective manner. Participants will randomly assigned to one of three colonoscopy preparation groups (i) a written hand out containing all information required for bowel preparation (standard care) (ii) standard care and in addition a video call with a professional nurse conducted via digital devices and a free software (Zoom video communication or What's app application) (iii) standard care and in addition to a video call as described above using an explanatory short video on bowel preparation (video film), streamed to the patient's mobile device or computer.

NCT ID: NCT05735002 Not yet recruiting - Clinical trials for Chronic Mesenteric Ischemia

Promoting Early Diagnosis of Chronic Mesenteric Ischemia

PROMISE
Start date: April 1, 2023
Phase:
Study type: Observational

CMI is an incapacitating disease and timely diagnosis remains problematic. Despite the substantial compensatory capacity of the mesenteric circulation CMI is relatively common, its incidence being comparable to other well-known diseases like Crohn's disease. Diagnostic tools are needed for two purposes since the exclusion of CMI currently requires a cumbersome complication-prone diagnostic workup and since a definitive diagnosis is mainly established per exclusionem. First, a sensitive test is desirable to rule out CMI and avoid excessive diagnostic investigations. Quantification of mesenteric arterial calcification on computed tomography (CT) seems suitable for this purpose, synonymous with the coronary artery calcium score. Second, a specific test is required confirming CMI by detection of mucosal ischemia during a meal, when oxygen demand peaks. A breath test, based on the requirement of oxygen to absorb and metabolize 13C-butyrate in the enterocyte, could detect mucosal ischemia Objective: Facilitating diagnosis of chronic mesenteric ischemia (CMI) using 1) the mesenteric artery calcium score (MACS) and 2) mucosal ischemia detection by butyrate breath testing Study design: Multicentre prospective cohort studies.

NCT ID: NCT05737342 Not yet recruiting - Metabolic Syndrome Clinical Trials

Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)

NCT ID: NCT05737355 Not yet recruiting - Hyperlipidemias Clinical Trials

Effect of ANKASCIN 568-P Products Regulating Blood Lipid

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)

NCT ID: NCT05738590 Not yet recruiting - Clinical trials for Inflammatory Muscle Disease

Inflammatory and Degenerative Muscle Disease

Start date: April 1, 2023
Phase:
Study type: Observational

Correlation between clinical , ultrasonographical, neurophysiological and histopathological findings in muscle diseases of different etiologies.

NCT ID: NCT05740748 Not yet recruiting - Asthma, Allergic Clinical Trials

Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

Asthma is a condition where small inhaled particles can cause inflammation in the lung leading to constriction of airways and wheeze. Mast cells are immune cells in airways that can release chemical causing constriction of the airways and wheeze. Tezepelumab is an injectable medication that improves asthma by stopping inflammation, but the effect on mast cells is not known. Tezepelumab was approved in Canada July 2022 for treatment of severe asthma. Tezepelumab is not approved for treatment of mild asthma by any health authority, except for use in research studies like this. This study will examine the effect of tezepelumab on mast cells and airway constriction to understand the mechanisms of asthma, and which patients will benefit most from drugs like tezepelumab.

NCT ID: NCT05746000 Not yet recruiting - Clinical trials for Cardiometabolic Syndrome

A Nutrition Education Module to Modify Sugar Consumptions Among Individuals With Cardio Metabolic Risks

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The goal of this feasibility study is to assess the feasibility of a nutrition education module in modifying sugar consumption among individuals with cardiometabolic risk. The main questions it aims to answer are: - Is the nutrition education (focusing on modifying sugars intake) intervention feasible to individuals with cardiometabolic risk? - Can the intervention be delivered as planned and works as intended? - What are the experiences, perspective and barriers of individuals with cardiometabolic risk when receiving the nutrition education intervention? - Is the nutrition education intervention efficient in modifying the eating behaviour including the sugar consumption among individuals with cardiometabolic risk? Participants in the Control Group and Intervention Group will attend three standard diet counselling, with additional sugar education for the Intervention Group.

NCT ID: NCT05746858 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)

MIMOSA
Start date: April 1, 2023
Phase:
Study type: Observational

The goal of this study is to identify biomarkers that will predict outcome to standard and targeted therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The specific aims of the present project are: 1. To explore associations between expression of target antigens on surface of neoplastic cells of DLBCL patients and response to target therapies 2. To identify specific miRNA signatures as predictors of response to upfront and salvage immune-chemotherapies in DLBCL patients. 3. To refine the diagnosis and molecular profiling of DLBCL, and to provide biological information of prognostic relevance in the setting of innovative treatments of patients with DLBCL.